A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
Completed · Phase 1
Conditions studied: Metastatic Cancer
In brief
This is a Phase 1 study during which patients with advanced cancer will receive investigational study drug ARRY-382. Patients will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 50 patients from the US will be enrolled in this study.
Key facts
- Study ID
- NCT01316822
- Run by
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- People needed
- 26
- Starts
- 2011-03-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2020-09-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.